# Aifeizhiyao





Canonical: https://uniquebase.ai/companies/UB-C9363
Stable identifier: UB-C9363
Snapshot captured: 2026-10-16T01:37:30.476Z
English updated: 2026-10-16T01:39:37.439Z

## Funding

Listed 2 records.

- 2026-09-03 · 亿元人民币 · Angel · 襄禾资本 · https://www.cnr.cn/mspd/sywzl/20260903/t20260903_527803600.shtml
  > On September 3, 2026, Beijing-based AIPher, an AI-native drug developer, raised RMB 100 million in an Angel round led by Xianghe Capital. Gao Bowen serves as CEO, Lan Yanyan as chief scientist and Zhang Yaqin as chief scientific advisor. (translated source brief)
- 2026-07-08 · Undisclosed · Equity · 华控技术转移有限公司
  > On 2026-07-08, according to Xiniu Data, Aifeizhiyao completed equity financing for an undisclosed amount. Investors were Huakong Technology Zhuanyi Co., Ltd.. The company is an AI-native new drug developer. (translated source brief)

## Valuation

Listed 2 records.

- 2026-09-03 · amount unavailable · Angel · 襄禾资本 · https://www.cnr.cn/mspd/sywzl/20260903/t20260903_527803600.shtml
  > On September 3, 2026, Beijing-based AIPher, an AI-native drug developer, raised RMB 100 million in an Angel round led by Xianghe Capital. Gao Bowen serves as CEO, Lan Yanyan as chief scientist and Zhang Yaqin as chief scientific advisor. (translated source brief)
- 2026-07-08 · amount unavailable · Equity · 华控技术转移有限公司
  > On 2026-07-08, according to Xiniu Data, Aifeizhiyao completed equity financing for an undisclosed amount. Investors were Huakong Technology Zhuanyi Co., Ltd.. The company is an AI-native new drug developer. (translated source brief)

## Revenue

No revenue records are listed yet.


## Team

No published team profiles are linked yet.

## Products

No published products profiles are linked yet.

## Investors

- [华控技术转移有限公司](/institutions/huakong-technology-zhuanyi-co-ltd)
- [襄禾资本](/institutions/xianghe-capital)

## Sources

- No source links are available for this profile.